Cargando…

Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice

SIMPLE SUMMARY: A diagnosis of diffuse large B-cell lymphoma in our therapeutic era should be implemented by the definition of the cell of origin, additional immunohistochemistry (i.e., BCL2 and MYC), and by fluorescent in-situ hybridization. The next step, suggested by the seminary works we will di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visco, Carlo, Tanasi, Ilaria, Quaglia, Francesca Maria, Ferrarini, Isacco, Fraenza, Costanza, Krampera, Mauro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600909/ https://www.ncbi.nlm.nih.gov/pubmed/33050534 http://dx.doi.org/10.3390/cancers12102913

Ejemplares similares

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
por: Kersten, M J, et al.
Publicado: (2014)

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
por: Kraan, W, et al.
Publicado: (2013)

CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma
por: Trøen, Gunhild, et al.
Publicado: (2013)

Prevalence And Clinical Significance Of Oncogenic CD79B And MYD88 Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China
por: Chen, Yan-ping, et al.
Publicado: (2019)

The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment
por: Ferrarini, Isacco, et al.
Publicado: (2020)

An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma
por: Ferrarini, Isacco, et al.
Publicado: (2023)

COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review
por: Bonuomo, Valentina, et al.
Publicado: (2021)

Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants‐enriched diffuse large B‐cell lymphomas
por: L'Imperio, Vincenzo, et al.
Publicado: (2022)

Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis
por: Lovato, Ester, et al.
Publicado: (2023)

Occurrence of MYD88L265P and CD79B mutations in diffuse large b cell lymphoma with bone marrow infiltration: A case report
por: Huang, Wen-Ye, et al.
Publicado: (2022)

MYD88(L265P) and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy
por: Chen, Rongrong, et al.
Publicado: (2022)

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma
por: Ebid, Osama Abd El Hameed, et al.
Publicado: (2023)

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
por: Munshi, Manit, et al.
Publicado: (2020)

MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
por: Qin, Yan, et al.
Publicado: (2023)

Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma
por: Fogliatto, Laura, et al.
Publicado: (2019)

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis
por: Vermaat, Joost S., et al.
Publicado: (2020)

PB2403: THE FREQUENCY OF L265P MUTATION IN MYD88 GENE AT DIFFUSE LARGE B-CELL LYMPHOMA
por: Dubrovina, Anastasiya, et al.
Publicado: (2023)

Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper
por: Bailly, Sarah, et al.
Publicado: (2022)

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
por: Lee, Ju-Han, et al.
Publicado: (2017)

Disrupting myddosome assembly in diffuse large B-cell lymphoma cells using the MYD88 dimerization inhibitor ST2825
por: Wang, Xin, et al.
Publicado: (2019)

PB2355: CORRELATION OF MYD88 AND TNFAIP3 MUTATIONS WITH CLINICO-HEMATOLOGICAL PROFILE IN DIFFUSE LARGE B CELL LYMPHOMA
por: Shaat, Rana, et al.
Publicado: (2023)

Synergistic cooperation and crosstalk between MYD88(L265P) and mutations that dysregulate CD79B and surface IgM
por: Wang, James Q., et al.
Publicado: (2017)

Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent Inflammation
por: Luo, Wu, et al.
Publicado: (2022)

Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia
por: Takam Kamga, Paul, et al.
Publicado: (2019)

Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR
por: Niu, Jing, et al.
Publicado: (2020)

MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway
por: Guo, Xiuchen, et al.
Publicado: (2023)

High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment
por: Yu, Sisi, et al.
Publicado: (2018)

The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain
por: Minderman, Marthe, et al.
Publicado: (2023)

The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine
por: Ferrarini, Isacco, et al.
Publicado: (2022)

Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling
por: Cardona Gloria, Yamel, et al.
Publicado: (2021)

PB2397: TRANSCRIPTOME ANALYSIS OF DIFFUSE LARGE B-CELL LYMPHOMA CELLS EXPRESSING MYD88 L265P REVEALS CD44, LGALS3, NFKBIZ AND BATF AS DOWNSTREAM TARGETS OF ONCOGENIC NF-ΚB SIGNALING.
por: Turi, Marcello, et al.
Publicado: (2023)

Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas
por: Shin, Sang-Yong, et al.
Publicado: (2016)

The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma
por: Elbaz, Osama, et al.
Publicado: (2023)

Extracellular Vesicle-Dependent Communication Between Mesenchymal Stromal Cells and Immune Effector Cells
por: Bazzoni, Riccardo, et al.
Publicado: (2020)

Lipopolysaccharide-induced NF-κB nuclear translocation is primarily dependent on MyD88, but TNFα expression requires TRIF and MyD88
por: Sakai, Jiro, et al.
Publicado: (2017)

Immunogenicity of recurrent mutations in MYD88 and EZH2 in non-Hodgkin lymphomas
por: Nielsen, Julie S, et al.
Publicado: (2015)

Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation
por: Quaglia, Francesca Maria, et al.
Publicado: (2019)

Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling
por: Turi, Marcello, et al.
Publicado: (2023)

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
por: Ansell, S M, et al.
Publicado: (2014)

Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study
por: Mohamed, Asmaa Hussein, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fiaslgiom5ov28p64r8npjpkvv